Biotech Mesoblast seeks up to $150m (Adelaide Now)
BIOTECHNOLOGY company Mesoblast is raising up to $150 million, a person familiar with the matter says.
Bell Potter was leading the raising at $6.30 a share, representing a 2.2 per cent discount to the stock's last-traded price, the person said.
Mesoblast is targeting a market estimated to be worth more than $US800m ($784m) in the US by developing a product to treat patients with degenerative spinal discs, which it says is less invasive than approved competing treatments.
Its product uses stem cells to grow bone and fuse vertebrae together, avo...
